21 Dec 2022
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
Author: admintech | Filed under: Press ReleaseRGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of CLN2 disease, the most common form of Batten disease Patient dosed under a single-patient investigator-initiated study of RGX-181 Company announces approval of CTA for…